

# Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 10 February 2021

Situation Report No. 231 - Kingdom of Bahrain

11<sup>th</sup> of February, 2021



	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
<b>Total</b>	106,555,206	2,333,446	5,898,784	130,069
<b>New</b>	647,722 in 2 days	18,924 in 2 days	47,369 in 2 days	768 in 2 days

## Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
<b>Total</b>	109,604	102,725	391	6,488	58	2,846,657
<b>New</b>	1556 in 2 days	1,096 in 2 days	8 in 2 days	-	-	26,647 in 2 days

## HIGHLIGHTS

- The mortality were: 4 Bahraini citizens [3 female( 64, 66 and 66 years old) and 1 male (80 years old)], and 4 expatriates [1 female (79 Year old ) and 3 male (38, 60 and 66 years old)].
- Increasing number of citizens and residents continue to take COVID-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed that total number of individuals vaccinated as of 10 February 2021 is 219,595.
- The Kingdom of Bahrain authorized the emergency use of the Sputnik V vaccine.
- MOH Undersecretary underlining the national duty, called for a full public commitment on COVID-19 preventive measures.
- Several medical experts warned that Bahrain could face a third wave of the coronavirus pandemic, urging people to take the two-dosed COVID-19 vaccines.
- Prayers will be suspended in all Mosques from today for two weeks to contain the spread of COVID-19.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immun assay; see link below.
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health; see link below.
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing; see link below.
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum; see link below.
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers; see link below.
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19; see link below.
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum; see link below.
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines; see link below.
- WHO: Online global consultation on contact tracing for COVID-19, 9-11 June 2020; see link below.
- WHO: COVID-19 Virtual Press conference transcript - 1 February 2021; see link below.
- WHO: Contact tracing in the context of COVID-19; see link below.
- WHO: Background document on the mRNA-1273 vaccine (Moderna) against COVID-19; see link below.
- WHO: COVID-19: Occupational health and safety for health workers; see link below.


## IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO's COVID-19 weekly situation reports: [https://www.who.int/docs/default-source/coronavirus/situation-reports/20200817-weekly-epi-update-1.pdf?sfvrsn=b649a76\\_4](https://www.who.int/docs/default-source/coronavirus/situation-reports/20200817-weekly-epi-update-1.pdf?sfvrsn=b649a76_4)
- WHO's COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies: <https://www.who.int/news/item/21-02-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/25v5d9r>
- WHO: Emergency Global Supply Chain System(COVID-19) catalogue: <https://www.who.int/publications/m/item/emergency-global-supply-chain-system-covid-19-catalogue>
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immun assays: <https://bit.ly/2RQwVf>
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination: <https://bit.ly/2J0wvWQ>
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises: <https://www.who.int/publications/m/item/9789210013467>
- COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/m/item/10665337553>
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding: [https://www.who.int/publications/m/item/WHO-2019-nCoV-Policy\\_Brief\\_EUD\\_placebo-controlled\\_vaccine\\_trials-2020.1](https://www.who.int/publications/m/item/WHO-2019-nCoV-Policy_Brief_EUD_placebo-controlled_vaccine_trials-2020.1)
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health: <https://www.who.int/publications/m/item/9789210013440>
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing: [https://www.who.int/publications/m/item/WHO-2019-nCoV-vaccines-SAGE\\_recommendation-BNT162b2-2021.1](https://www.who.int/publications/m/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1)
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum: <https://www.who.int/news/item/12-01-2021-global-scientists-double-down-on-sars-cov-2-variants-research-at-who-hosted-forum>
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers: [https://www.who.int/publications/m/item/WHO-2019-nCoV-essential\\_health\\_services-monitoring-2021.1](https://www.who.int/publications/m/item/WHO-2019-nCoV-essential_health_services-monitoring-2021.1)
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: <https://www.who.int/publications/m/item/background-document-on-mrna-vaccine-bnt162b2-pfizer-biontech-against-covid-19>
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum: <https://www.who.int/news/item/16-01-2021-scientists-tackle-vaccine-safety-eficacy-and-access-at-global-r-d-forum>
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines: <https://www.who.int/news/item/12-01-2021-emergency-committee-on-covid-19-advises-on-variants-vaccines>
- WHO: COVID-19 Virtual Press conference transcript - 1 February 2021: <https://www.who.int/publications/m/item/online-global-consultation-on-contact-tracing-for-covid-19-9-11-june-2020>
- WHO: Online global consultation on contact tracing for COVID-19, 9-11 June 2020: <https://www.who.int/publications/m/item/online-global-consultation-on-contact-tracing-for-covid-19-9-11-june-2020>
- WHO: COVID-19 Virtual Press conference transcript - 1 February 2021: <https://www.who.int/publications/m/item/covid-19-virtual-press-conference-transcript-1-february-2021>
- WHO: Contact tracing in the context of COVID-19: <https://www.who.int/publications/m/item/contact-tracing-in-the-context-of-covid-19>
- WHO: Background document on the mRNA-1273 vaccine (Moderna) against COVID-19: <https://www.who.int/publications/m/item/background-document-on-the-mrna-1273-vaccine-moderna-against-covid-19>
- WHO: COVID-19: Occupational health and safety for health workers: [https://www.who.int/publications/m/item/WHO-2019-nCoV-HCW\\_ajcnc-2021.1](https://www.who.int/publications/m/item/WHO-2019-nCoV-HCW_ajcnc-2021.1)


## IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: [NAli5@health.gov.bh](mailto:NAli5@health.gov.bh)
- International Health Regulations focal person is Dr. Kubra Salman, email: [knasser@health.gov.bh](mailto:knasser@health.gov.bh)

Number of New Cases



Total Number of Cases



Number of New Deaths

